If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
== Diagnosis == The symptoms of a metabolic myopathy can be easily confused with the symptoms of another disease. As genetic sequencing research progresses, a non-invasive neuromuscular panel DNA test can help make a diagnosis. Whole genome sequencing is required in more complex cases. If the DNA test is inconclusive (negative or VUS), then a muscle biopsy is necessary for an accurate diagnosis. In mitochondrial myopathies involving a single mtDNA deletion, DNA would have to be tested from affected muscle tissue rather than saliva or blood as unaffected tissues would show normal or near normal levels of mtDNA. A blood test for creatine kinase (CK) can be done under normal circumstances to test for signs of tissue breakdown, or with an added cardio portion that can indicate if muscle breakdown is occurring. In metabolic myopathies, baseline CK is either normal or elevated. An electromyography (EMG) test is sometimes taken in order to rule out other disorders if the cause of fatigue is unknown. In metabolic myopathies, the EMG is either normal or myopathic, but spontaneous activity is usually absent. An exercise stress test can be used to determine an inappropriate rapid heart rate (sinus tachycardia) response to exercise, which is seen in GSD-V, other glycogenoses, and mitochondrial myopathies. A 12 Minutes Walk Test (12MWT) can also be used to determine "second wind" which is also seen in McArdle disease (GSD-V) and phosphoglucomutase deficiency (PGM1-CDG/CDG1T/GSD-XIV).
The Parliament of Canada consists of the monarch, the Senate and the House of Commons. Only members of the House of Commons are referred to as members of Parliament (French: député); members of the Senate are called Senators (French: sénateur). There are currently 105 seats in the Senate and 343 in the House of Commons. Members of Parliament are elected, while senators are appointed by the governor general on behalf of the sovereign at the direction of the prime minister. Retirement is mandatory for senators upon reaching the age of 75 years. Each province (and territory) has its own legislature, with each member usually known as a Member of the Legislative Assembly (MLA). In certain provinces, legislators carry other titles: Member of Provincial Parliament (MPP) in Ontario, Member of the National Assembly (MNA) in Quebec (French: député) and Member of the House of Assembly (MHA) in Newfoundland and Labrador. The provincial upper houses were eliminated between 1876 (Manitoba) and 1968 (Quebec).
== Hematopoiesis == The various cell types of the mononuclear phagocyte system are all part of the myeloid lineage from the CFU-GEMM (precursor of granulocytes, erythrocytes, monocytes and megakaryocytes).
=== Sleepwalking and complex sleep behaviors === Zolpidem has drawn significant media attention due to reports of complex sleep behaviors (CSBs), including sleepwalking, sleep-driving, and other activities performed while not fully conscious. Notable incidents include media reports in the United States concerning events such as Congressman Patrick Kennedy's motor vehicle accident and in Australia following a fatal 20 metres (66 ft) fall from the Sydney Harbour Bridge involving an individual reportedly under the influence of zolpidem. In May 2018, actress Roseanne Barr attributed a controversial remark on Twitter to the effects of zolpidem. Barr's tweet compared Valerie Jarrett, a Black woman and former advisor to Barack Obama, to an ape. The comparison sparked widespread condemnation and led to the cancellation of Roseanne. The incident prompted Sanofi, the manufacturer of Ambien, to issue a public statement clarifying that "racism is not a known side effect" of the medication.
The deficiency in anchoring fibrils impairs the adherence between the epidermis and the underlying dermis. This deficiency occurs due to the genetic mutation(s) in the COL7A1 gene in chromosome 3. The COL7A1 gene in chromosome 3 is responsible for coding for type VII collagen, a protein that assists in helping anchor the epidermis and dermis. Thus, the skin of DEB patients is highly susceptible to mild to severe blistering, depending on the subtype. Collagen VII is also associated with the epithelium of the esophageal lining, and DEB patients may have chronic scarring, webbing, and obstruction of the esophagus. Affected individuals are often severely malnourished due to trauma to the oral and esophageal mucosa and require feeding tubes for nutrition. They also have iron-deficiency anemia of uncertain origin, which leads to chronic fatigue. Open wounds on the skin heal slowly or not at all, often scarring extensively, and are particularly susceptible to infection. Many individuals bathe in a bleach and water mixture to fight off these infections. The chronic inflammation leads to errors in the DNA of the affected skin cells, which in turn causes squamous cell carcinoma (SCC). The majority of these patients die before the age of 30, either of SCC or complications related to DEB. The chronic inflammatory state seen in recessive dystrophic epidermolysis bullosa (RDEB) may cause small fiber peripheral neuropathy (SFN). RDEB patients have reported the sensation of pain in line with neuropathic pain qualities.
Sources: en.wikipedia.org
Jean becomes possessed by the Phoenix Force once more and Wolverine has no other choice but to kill her with his claws. Wolverine learns about the existence of X-23. He initially believes her to be a clone, raised to be a perfect assassin. X-23 later goes by the name Laura. She is eventually enrolled at the Xavier Institute. She quickly accepts Wolverine as a father figure, and eventually they learn that he is actually her biological father. Wolverine is brainwashed by the Hand and battles S.H.I.E.L.D., but eventually turns against them with the help of Elektra. After Scarlet Witch drastically transforms reality, Wolverine is able to recall memories of his previous life, overcoming his traumatic amnesia; he discovers that he has a son named Daken, who has been brainwashed and made a living weapon. Cyclops orders Wolverine to reform X-Force. Wolverine splits from Cyclops and opens a new school in Westchester, New York, the "Jean Grey School for Higher Learning". The Phoenix Force returns to Earth, causing conflict between the X-Men and the Avengers. Wolverine takes the side of the Avengers. Cyclops becomes possessed by the Phoenix Force and kills Professor X. A virus turns off Wolverine's healing factor. He discovers that Doctor Abraham Cornelius, the founder of the Weapon X program, has placed a bounty on his head. Wolverine gets covered in adamantium after confronting him, and dies from suffocation. Laura begins wearing a variation of Wolverine's costume and adopts his codename. Wolverine is eventually resurrected by Persephone, a mutant who can raise the dead.
By replacing the gene with a new version fused to a green fluorescent protein marker or similar, expression may be directly quantified in live cells. This is done by imaging using a fluorescence microscope. It is very difficult to clone a GFP-fused protein into its native location in the genome without affecting expression levels, so this method often cannot be used to measure endogenous gene expression. It is, however, widely used to measure the expression of a gene artificially introduced into the cell, for example via an expression vector. By fusing a target protein to a fluorescent reporter, the protein's behavior, including its cellular localization and expression level, can be significantly changed. The enzyme-linked immunosorbent assay works by using antibodies immobilised on a microtiter plate to capture proteins of interest from samples added to the well. Using a detection antibody conjugated to an enzyme or fluorophore the quantity of bound protein can be accurately measured by fluorometric or colourimetric detection. The detection process is very similar to that of a Western blot, but by avoiding the gel steps more accurate quantification can be achieved.
== Prevention == Since risk factors are not known and vary among individuals with hyperandrogenism, there is no sure method to prevent the condition. Accordingly, more long-term studies are needed to find a cause of the condition before a sufficient method of prevention can be established. Despite this, there are a few things that can help avoid long-term medical issues related to hyperandrogenism and PMOS. Getting checked by a medical professional for hyperandrogenism — especially if one has a family history of the condition, irregular periods, or diabetes — can be beneficial. A healthy weight and diet may reduce the chances, as continued exercise and a healthy diet lead to an improved menstrual cycle, decreased insulin levels, and lowered androgen concentrations.
== Prime ministers == The official counting of prime ministers starts with the first president of the Council of Ministers of the constitutional monarchy. The first column shows the name (and title during the monarchy) of each office holder, with the second and third column showing the start and end of term. A fourth column counts the duration of each term. The next column shows each election won by each Prime Minister, followed by the color and political affiliation of the holder. Then, there's a column listing each constitutional governments headed by each Prime Minister, and finally, a last column showing the head of state during the term of each office holder, between 1834 and 1910, a Monarch, and since 1910, a President. The colors indicate the political affiliation: No party/independent Chartist/Chamorro Septemberist Regenerator Historic Reformist Progressist Liberal Regenerator
2-Hydroxybutyrate, the conjugate base of 2-hydroxybutyric acid, is produced in mammalian tissues (principally hepatic) that catabolize L-threonine or synthesize glutathione. Oxidative stress or detoxification demands can dramatically increase the rate of hepatic glutathione synthesis. Under such metabolic stress conditions, supplies of L-cysteine for glutathione synthesis become limiting, so homocysteine is diverted from the transmethylation pathway forming methionine into the transsulfuration pathway forming cystathionine. 2-Hydroxybutyrate is released as a byproduct when cystathionine is cleaved to cysteine that is incorporated into glutathione. Chronic shifts in the rate of glutathione synthesis may be reflected by urinary excretion of 2-hydroxybutyrate. α-hydroxybutyrate may be useful as an early indicator of insulin resistance in non-diabetic subjects. Moreover, elevated serum α-hydroxybutyrate predicts worsening glucose tolerance.
Sources: en.wikipedia.org
For example, lung resistance-related proteins, otherwise referred to as major vault proteins, are located on the nuclear membrane of cells and typically mediate nucleocytoplasmic transport. Here, the regulation of compounds between the nucleus and cytoplasm is a process that can be overexpressed by cancer cells to transport DNA-targeted chemotherapeutic drugs away from the nucleus, and essentially restrict these drugs from successfully interacting with their targets. Without reducing the total intracellular chemotherapeutic drug concentration, cancer cells have developed mechanisms to successfully dismantle drug-target interactions and confer resistance to multiple chemotherapeutic drugs. An additional mechanism of resistance interfering with drug-target interaction can be demonstrated by mutations in genes that encode for drug target proteins, such as tubulin. Broadly, tubulin proteins make up intracellular structures known as microtubules that play a fundamental role in cellular shape, division, signaling, and movement, thus making them a particular promising site of target for chemotherapeutic drugs. By altering or inhibiting microtubule dynamics in cancer cells, drugs can prohibit successfully cell division and induce the direct activation of adoptotic pathways. However, mutations that produce physical alterations in tubulin protein structure, can interfere with the several tubulin binding sites and inhibit the effective interaction and activity of these chemotherapeutic drugs.
where ± refers to a positive or negative particle, Ip is the incident ion current, f±i is the fraction of particles sputtered as ions, Si is the sputtering yield of both ions and neutrals, Ci is the concentration of the ith element (corrected for isotopic abundance) in the sputtered volume, ηi is the collection efficiency of the SIMS instrument, Ip = d2j/4, d is the diameter of a Gaussian-shaped beam, and j is the current density.
This was from the notion that depression was primarily due to norepinephrine deficits, partly based on the fact that drugs that relieve depression increase brain norepinephrine levels. To date, a great number of potent and selective and mixed norepinephrine reuptake inhibitors (NRIs) have been marketed as antidepressants. The first commercially available selective norepinephrine reuptake inhibitor (sNRI) was reboxetine (Edronax) and was developed as a first-line therapy for major depressive disorder. The selectivity of reboxetine for the norepinephrine transporter (NET) results in benign side effect profile because the drug is well tolerated. In the laboratories of Chemistry of Farmitalia Carlo Erba (Milan, Italy), reboxetine was synthesized according to the general method described by Melloni et al. In 1993 Kabi Pharmacia, Swedish based pharmaceutical giant, bought Farmitalian and in 2003 Pfizer bought Pharmacia. Atomoxetine (Strattera) is another potent and selective NRI which is also effective and well tolerated treatment for adults with ADHD. This drug was the first ADHD treatment to be specially approved for adult use. Studies showed that atomoxetine is a nonstimulant and carries negligible risk of abuse. This discovery was groundbreaking as a beneficial new treatment option for adults with ADHD, specially those patients at risk of substance abuse.
Action – Batman: Arkham City Artistic Achievement – Rayman Origins Audio Achievement – Battlefield 3 Best Game – Portal 2 Debut Game – Insanely Twisted Shadow Planet Family – LittleBigPlanet 2 Game Design – Portal 2 Game Innovation – LittleBigPlanet 2 Mobile & Handheld – Peggle HD Online – Browser – Monstermind Online Multiplayer – Battlefield 3 Original Music – L.A. Noire Performer – Mark Hamill (as The Joker, Batman: Arkham City) Sports/Fitness – Kinect Sports: Season Two Story – Portal 2 Strategy – Total War: Shogun 2 BAFTA Ones To Watch Award (in association with Dare to Be Digital) – Tick Tock Toys GAME Award of 2011 – Battlefield 3 Special – Markus Persson
== Dried plasma spot == This technology is similar to dried blood spot sampling however instead of collecting whole blood on a membrane, it separates red blood cells from plasma. A dried plasma spot (DPS) is usually a drop of capillary blood on a plasma separation card, the first membrane will filter all the red blood cells, while the second membrane aborbs the cell free plasma. This method is ideal for processing and storage of plasma.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.